Episurf’s implants approved for sale in Malaysia
Episurf Medical (NASDAQ: EPIS B) today announces that the Medical Device Authority (MDA) in Malaysia has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Malaysian market. The approval follows a review process.
“It is exciting to see the progress of the regulatory work for Episurf’s devices towards new markets. This regulatory approval opens up the market and enables us to work with our distributor towards the next important steps in Malaysia“, says Michael Näsström, Head of Quality and Regulatory Affairs at Episurf Medical.
CisionBlockPro\Cision\FeedItem Object
(
[HtmlCompanyInformation:protected] => <p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><strong><span style="font-size:10pt">About Episurf Medical</span></strong></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.</em></p>
<p style="font-family:arial,helvetica,sans-serif; font-size:10pt"><span style="font-family:arial,helvetica,sans-serif; font-size:10pt"><em>This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.35 CET on 17 January 2022.</em></span></p>
[HtmlContact:protected] => <p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><strong><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">For more information, please contact:</span></strong></p>
<p style="font-family: arial, helvetica, sans-serif; font-size: 10pt;"><span style="font-size: 10pt;">Pål Ryfors, CEO, Episurf Medical<br /></span><span style="font-size: 10pt; font-family: arial,helvetica,sans-serif;">Tel:</span><span style="font-size: 10pt;">+46 (0) 709 62 36 69<br /></span><span style="font-size: 10pt;">Email: </span><a href="mailto:pal.ryfors@episurf.com">pal.ryfors@episurf.com</a></p>
[HtmlTitle:protected] => <h1 style="line-height:120%;"><span style="font-family:arial,helvetica,sans-serif"><strong>Episurf’s implants approved for sale in Malaysia</strong></span></h1>
[HtmlHeader:protected] =>
[HtmlIntro:protected] =>
[Body:protected] => Episurf Medical (NASDAQ: EPIS B) today announces that the Medical Device Authority (MDA) in Malaysia has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Malaysian market. The approval follows a review process.
“It is exciting to see the progress of the regulatory work for Episurf’s devices towards new markets. This regulatory approval opens up the market and enables us to work with our distributor towards the next important steps in Malaysia“, says Michael Näsström, Head of Quality and Regulatory Affairs at Episurf Medical.
[HtmlBody:protected] => <p style="margin-bottom:11px;margin-top:12px"><span><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:times new roman,times"><span style="font-family:arial,helvetica,sans-serif"><span style="color:#333333">E</span></span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif"><span style="color:black">pisurf Medical (NASDAQ: EPIS B) today announces that the Medical Device Authority (MDA) in Malaysia has approved the company’s implant technologies Episealer® Knee and Episealer® Talus for the Malaysian market. </span></span></span><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif"><span style="color:black">The approval follows a review process.</span></span></span></span></span></span></span></p>
<p style="margin-bottom:11px"><span><span style="font-size:12pt"><span style="background-color:white"><span style="font-family:times new roman,times"><em><span style="font-family:arial,helvetica,sans-serif"><span style="color:#333333">“I</span></span></em><em><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif"><span style="color:black">t is exciting to see the progress of the regulatory work for Episurf’s devices towards new markets. </span></span></span></em><em><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif"><span style="color:black">This regulatory approval opens up the market and enables us to work with our distributor towards the next important steps in Malaysia“</span></span></span></em><span style="font-size:11pt"><span style="font-family:arial,helvetica,sans-serif"><span style="color:black">, says Michael Näsström, Head of Quality and Regulatory Affairs at Episurf Medical. </span></span></span></span></span></span></span></p>
[ServiceCategories:protected] => Array
(
[0] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => EU Transparency SE
[Name:protected] => SeFsaCategoryCode
[Value:protected] => S6
)
[1] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => OMX Filing (OMX CNS)
[Name:protected] => OMX CategoryCode
[Value:protected] => 428
)
[2] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Twitter
[Name:protected] => Twitter
[Value:protected] => 9341
)
[3] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => LinkedIn
[Name:protected] => LinkedIn
[Value:protected] => 12311
)
[4] => CisionBlockPro\Cision\ServiceCategory Object
(
[ServiceName:protected] => Facebook
[Name:protected] => Facebook
[Value:protected] => 14035
)
)
[LogoUrl:protected] => https://mb.cision.com/Public/14691/logo/96c29c854b230ac3_org.png
[CompanyInformation:protected] => About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.35 CET on 17 January 2022.
[Contact:protected] => For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
[Header:protected] =>
[Keywords:protected] => Array
(
[0] => Episurf Medical
[1] => EpiSurf
[2] => Episealer
)
[QuickFacts:protected] => Array
(
)
[Categories:protected] => Array
(
)
[Videos:protected] => Array
(
)
[Files:protected] => Array
(
[0] => CisionBlockPro\Cision\File Object
(
[IsMain:protected] => 1
[MediaType:protected] => File
[Url:protected] => https://mb.cision.com/Main/14691/3486946/1520980.pdf
[FileName:protected] => wkr0006.pdf
[Title:protected] => Episurf’s implants approved for sale in Malaysia
[Description:protected] => Episurf’s implants approved for sale in Malaysia
[CreateDate:protected] => 2022-01-17T07:35:06.427Z
[Keywords:protected] => Array
(
)
[Extension:protected] => pdf
)
)
[Quotes:protected] => Array
(
)
[ExternalLinks:protected] => Array
(
)
[EmbeddedItems:protected] => Array
(
)
[Id:protected] => 4160104
[EncryptedId:protected] => 480FC91A53E1C356
[IsRegulatory:protected] => 1
[PublishDate:protected] => 2022-01-17T07:35:00Z
[LastChangeDate:protected] => 2022-01-17T07:35:06.41Z
[Title:protected] => Episurf’s implants approved for sale in Malaysia
[Intro:protected] =>
[IptcCode:protected] => 04016003
[InformationType:protected] => PRM
[LanguageCode:protected] => en
[CountryCode:protected] => se
[CanonicalUrl:protected] =>
[CisionWireUrl:protected] => https://news.cision.com/episurf/r/episurf-s-implants-approved-for-sale-in-malaysia,c3486946
[LanguageVersions:protected] => Array
(
)
[Images:protected] => Array
(
)
[Tickers:protected] => Array
(
[0] => stdClass Object
(
[Symbol] => EPIS B
[ISIN] => SE0003491562
[PrimaryListing] => 1
[IsShare] => 1
[MarketPlaceSymbol] => STO
[MarketPlaceName] => Stockholmsbörsen
[MarketPlaceBloombergCode] => SS
[MarketPlaceMarketWireCode] => OMX
[MarketPlaceIsRegulated] => 1
[MarketPlaceCountryCode] => SE
)
)
)